What Is the New Alzheimer’s Disease Medication – and Who Should Get It?
![placeholder-image](/sites/g/files/oketem336/files/styles/3_2_480x320/public/media/images/placeholder_1.jpeg.webp?itok=Af7aISTw)
Dr. Keith Vossel, Professor of Neurology, and Director of the Mary S. Easton Center for Alzheimer's Disease Research at UCLA, David Geffen School of Medicine, was featured in a June 15 UCLA Health article explaining the science behind the newly FDA approved Alzheimer's disease medication, Aduhelm (aducanumab).